Key Points
- CEO sale: Ionis CEO Brett Monia sold 29,430 shares on Feb. 6 at an average of $85.79 for a total of $2,524,799.70, leaving him with 254,497 shares—a roughly 10.37% reduction in his position.
- Stock snapshot: IONS opened near $84.29 with a market cap of about $13.65 billion, a 12‑month range of $23.95–$86.74, a negative P/E (-49.88), and 50/200‑day moving averages of $80.67/$68.64.
- Analyst and ownership picture: Analysts’ consensus is a “Moderate Buy” with an average target of $86.95 (several firms raised targets to $87–$97), and institutional investors hold roughly 93.86% of the stock.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CEO Brett Monia sold 29,430 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $85.79, for a total value of $2,524,799.70. Following the completion of the transaction, the chief executive officer owned 254,497 shares in the company, valued at approximately $21,833,297.63. This represents a 10.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Ionis Pharmaceuticals Price Performance
Shares of IONS stock opened at $84.29 on Wednesday. The firm has a market cap of $13.65 billion, a price-to-earnings ratio of -49.88 and a beta of 0.29. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $86.74. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The stock has a 50-day moving average price of $80.67 and a 200 day moving average price of $68.64.
Analysts Set New Price Targets
IONS has been the topic of several analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Ionis Pharmaceuticals in a report on Thursday, January 22nd. Piper Sandler upped their target price on shares of Ionis Pharmaceuticals from $77.00 to $87.00 and gave the company an "overweight" rating in a research report on Friday. TD Cowen restated a "buy" rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, December 3rd. Barclays initiated coverage on Ionis Pharmaceuticals in a report on Wednesday, January 28th. They issued an "overweight" rating and a $95.00 price objective for the company. Finally, Bank of America raised their target price on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the stock a "buy" rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $86.95.
Read Our Latest Stock Analysis on Ionis Pharmaceuticals
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IONS. Stanley Laman Group Ltd. acquired a new position in Ionis Pharmaceuticals during the third quarter valued at approximately $2,340,000. Norges Bank acquired a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $17,790,000. Massachusetts Financial Services Co. MA raised its stake in shares of Ionis Pharmaceuticals by 66.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 862,593 shares of the company's stock worth $56,431,000 after purchasing an additional 343,409 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Ionis Pharmaceuticals by 1,669.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 312,297 shares of the company's stock valued at $20,430,000 after buying an additional 294,643 shares during the last quarter. Finally, Capricorn Fund Managers Ltd bought a new position in shares of Ionis Pharmaceuticals in the third quarter valued at $10,650,000. 93.86% of the stock is currently owned by institutional investors.
About Ionis Pharmaceuticals
(
Get Free Report)
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
